Maralixibat

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Intrahepatic Cholestasis of Pregnancy

Conditions

Intrahepatic Cholestasis of Pregnancy

Trial Timeline

Apr 1, 2026 → Mar 31, 2028

NCT ID

NCT07389031

About Maralixibat

Maralixibat is a phase 2 stage product being developed by Mirum Pharmaceuticals for Intrahepatic Cholestasis of Pregnancy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07389031. Target conditions include Intrahepatic Cholestasis of Pregnancy.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04530994	Pre-clinical	Completed	—	—	Alagille Syndrome
NCT07389031	Phase 2	Recruiting	Apr 1, 2026	Mar 31, 2028	Intrahepatic Cholestasis of Pregnancy
NCT06553768	Phase 3	Recruiting	Oct 14, 2024	Feb 1, 2027	Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
NCT04729751	Phase 2	Completed	Sep 9, 2021	Dec 17, 2024	Progressive Familial Intrahepatic Cholestasis
NCT04524390	Phase 2	Completed	Jul 8, 2021	Feb 7, 2024	Biliary Atresia
NCT04168385	Phase 2	Completed	Jan 16, 2020	Sep 4, 2024	Cholestatic Liver Disease
NCT04185363	Phase 3	Completed	Jan 8, 2020	Apr 23, 2025	Progressive Familial Intrahepatic Cholestasis (PFIC)
NCT03905330	Phase 3	Completed	Jul 9, 2019	Sep 1, 2022	Progressive Familial Intrahepatic Cholestasis (PFIC)

Competing Products

20 competing products in Intrahepatic Cholestasis of Pregnancy

See all competitors

Product	Company	Stage	Hype Score
Apatinib	Jiangsu Hengrui Medicine	Phase 2	52
Apatinib and Adebrelimab in Combination With chemotherapy	Jiangsu Hengrui Medicine	Phase 2	52
Apatinib	Jiangsu Hengrui Medicine	Phase 2	52
Famitinib	Jiangsu Hengrui Medicine	Phase 2	52
Camrelizumab + Apatinib	Jiangsu Hengrui Medicine	Phase 2	52
Durvalumab + SNDX-6352	AstraZeneca	Phase 2	52
Durvalumab + Tremelimumab	AstraZeneca	Phase 2	52
Pemigatinib + Durvalumab	AstraZeneca	Phase 2	52
Durvalumab + Gemcitabine + Cisplatin	AstraZeneca	Phase 2	52
Pemigatinib	Incyte	Phase 2	49
A4250 (odevixibat)	Ipsen	Phase 3	74
Odevixibat	Ipsen	Pre-clinical	20
CGT4859	Cogent Biosciences	Phase 1/2	38
LUM001 (Maralixibat)	Mirum Pharmaceuticals	Phase 2	49
Maralixibat	Mirum Pharmaceuticals	Phase 3	74
Maralixibat	Mirum Pharmaceuticals	Phase 2	49
Volixibat + Placebo	Mirum Pharmaceuticals	Phase 2	49
Maralixibat	Mirum Pharmaceuticals	Phase 3	74
Maralixibat + Placebo	Mirum Pharmaceuticals	Phase 3	74
HMPL-453 + Rabeprazole	HUTCHMED	Phase 1	28

Other Products from Mirum Pharmaceuticals

Livmarli Oral ProductApproved